Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
ZacksBristol Myers’ (BMY) Opdivo combination regimen receives the European Commission’s approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Bristol Myers’ (BMY) Opdivo combination regimen receives the European Commission’s approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.